Literature DB >> 27079779

Medication adherence in patients with schizophrenia.

Stephanie V Phan1.   

Abstract

Medication nonadherence is common among patients with schizophrenia and due to a variety of factors including lack of insight, psychopathology, substance use disorder, issues associated with treatment, stigma, fragmentation of care, cultural influences, and socioeconomic status. Among this population, nonadherence is problematic because it can lead to decompensation or exacerbation of symptoms, relapse, rehospitalization or greater use of emergency psychiatric services, functional decline, and increased risk of death. Psychoeducational approaches alone are ineffective, but in combination with behavioral interventions, appear to be effective. Involving the patient's support system, in addition to other interventions, can improve treatment adherence. Many medication-related factors, such as effectiveness and tolerability of antipsychotics, regimen complexity, and past medication trials impact appropriate medication use. Therefore, optimizing the patient's pharmacotherapeutic regimens can improve adherence. Additional factors favorably influencing adherence include involving the patient in their treatment, fostering a therapeutic alliance, implementing/using reminder systems, and addressing substance use disorder. Medication nonadherence arises from multiple reasons that vary between patients. Thus, the most effective strategies to improve adherence are multifactorial and may involve both psychoeducational and behavioral techniques, as well as previously listed approaches. Strategies should be targeted toward the patient and their support system, whenever possible, to further improve the chances of appropriate medication use. Recognizing that all patients with schizophrenia are at risk for medication nonadherence is important. No one technique has been shown to be most effective; therefore, the risk for nonadherence should continually be assessed and multiple strategies should be targeted to the patient (and caregiver) and repeatedly implemented throughout the course of the patient's illness.
© The Author(s) 2016.

Entities:  

Keywords:  antipsychotics; medication compliance; nonadherence; schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 27079779     DOI: 10.1177/0091217416636601

Source DB:  PubMed          Journal:  Int J Psychiatry Med        ISSN: 0091-2174            Impact factor:   1.210


  16 in total

Review 1.  Can Smartphone Apps Assist People with Serious Mental Illness in Taking Medications as Prescribed?

Authors:  Cynthia L Bianco; Amanda L Myers; Stephen Smagula; Karen L Fortuna
Journal:  Sleep Med Clin       Date:  2020-12-07

Review 2.  Guidelines for the Pharmacotherapy of Schizophrenia in Adults.

Authors:  Gary Remington; Donald Addington; William Honer; Zahinoor Ismail; Thomas Raedler; Michael Teehan
Journal:  Can J Psychiatry       Date:  2017-07-13       Impact factor: 4.356

3.  Scale development and an educational program to reduce the stigma of schizophrenia among community pharmacists: a randomized controlled trial.

Authors:  Tomoo Fujii; Manako Hanya; Kenta Murotani; Hiroyuki Kamei
Journal:  BMC Psychiatry       Date:  2021-04-26       Impact factor: 3.630

4.  Analysis of Medication Adherence and Its Influencing Factors in Patients with Schizophrenia in the Chinese Institutional Environment.

Authors:  Wei Yu; Jie Tong; Xirong Sun; Fazhan Chen; Jie Zhang; Yu Pei; Tingting Zhang; Jiechun Zhang; Binggen Zhu
Journal:  Int J Environ Res Public Health       Date:  2021-04-29       Impact factor: 3.390

5.  Patients' experiences of long-acting injectable antipsychotics: a qualitative study.

Authors:  Lin-Ling Chiu; Chun-Hao Liu; Shu-Chung Lii; Chun-Lin Chu; Huang-Li Lin
Journal:  Neuropsychiatr Dis Treat       Date:  2019-07-03       Impact factor: 2.570

6.  Outcomes comparison of long-acting injectable antipsychotic initiation in treatment-naïve veterans in the inpatient versus outpatient setting.

Authors:  Nicole Romstadt; Erica Wonson
Journal:  Ment Health Clin       Date:  2018-03-26

7.  Cognitive behavioural therapy for auditory hallucinations in schizophrenia: A review.

Authors:  Maria Pontillo; Franco De Crescenzo; Stefano Vicari; Maria Laura Pucciarini; Roberto Averna; Ornella Santonastaso; Marco Armando
Journal:  World J Psychiatry       Date:  2016-09-22

8.  Aripiprazole Long-Acting Injection During First Episode Schizophrenia-An Exploratory Analysis.

Authors:  Gloria Giordano; Lorenzo Tomassini; Ilaria Cuomo; Emanuela Amici; Filippo Perrini; Gemma Callovini; Alfonso Carannante; Georgios D Kotzalidis; Sergio De Filippis
Journal:  Front Psychiatry       Date:  2020-01-08       Impact factor: 4.157

9.  The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index.

Authors:  Daniel Schöttle; Wolfgang Janetzky; Daniel Luedecke; Elmar Beck; Christoph U Correll; Klaus Wiedemann
Journal:  BMC Psychiatry       Date:  2020-02-22       Impact factor: 3.630

10.  Assessment of Real-Life Outcomes in Schizophrenia Patients according to Compliance.

Authors:  Zaina P Qureshi; Rezaul Khandker; Jason Shepherd; Salome Samant; Farid Chekani; Hollie M L Bailey
Journal:  Psychiatry J       Date:  2020-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.